Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 7/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 7/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.38 |
| ▸ | GRM5 | P41594 | 2/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8269480 | 0.83 | PARP1 (0.45) | PARP1 | |
| SCHEMBL26090855 | 0.82 | PDK4 (0.43) | SCN5ASCN9APDK4PARP1TNKS2 | |
| SCHEMBL31139432 | 0.82 | PDK4 (0.43) | SCN5ASCN9APDK4PARP1TNKS2 | |
| SCHEMBL1346305 | 0.81 | SCN9A (0.41) | SCN5ASCN9APDK4PARP1TNKS2 | |
| SCHEMBL4129240 | 0.74 | MAPK1 (0.43) | MAPK1PIM1PIM2 | |
| SCHEMBL31357123 | 0.73 | MAPK1 (0.53) | MAPK1 | |
| SCHEMBL31170824 | 0.73 | MAPK1 (0.53) | MAPK1 | |
| SCHEMBL4511304 | 0.72 | MAPK1 (0.46) | MAPK1 | |
| SCHEMBL8883453 | 0.72 | HTT (0.46) | MAPK1SCN5ASCN9A | |
| SCHEMBL16486497 | 0.71 | PIM1 (0.57) | PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063038-B2 | vasopressin V2 receptor agonists for treating nocturnal enuresis, nocturia, diabetes insipidus, urinary incontinence and bleeding disorders; {1-[4-(5H,11H-Benzo[e]pyrrolo[1,2- alpha ][1,4]diazepine-10-carbonyl)-2-methylbenzylcarbamoyl]-8-fluoro-1,2,3,4-tetrahydroquinolin-4-yl}acetic acid ethyl ester | VANTIA LIMITED (GB) | 2011-11-22 | — | — | US | disclosed |
| EP-1778677-B1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | VANTIA LTD (GB) | 2010-02-03 | — | — | EP | disclosed |
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | FERRING B.V. | 2008-09-25 | — | — | US | disclosed |
| EP-1778677-A1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | Ferring B.V. (NL) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006018443-A1 | HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS | FERRING B.V. (NL) | 2006-02-23 | — | — | WO | disclosed |
| EP-1627876-A1 | Heterocyclic condensed compounds useful as antidiuretic agents | FERRING B.V. (NL) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234250-A1 | Heterocyclic Condensed Compounds Useful as Antidiuretic Agents | AVPR2, AVPR1A, AVPR1B | MAPK1 2149/4885SCN5A 994/4885SCN9A 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.